page 5: 22 June ann: "In the event of outright clinical failure, being either serious safety or tolerability concerns and/or no
positive effects in the MIS416 treated patients compared to the placebo treated patients, then the
Director's believe that it would be difficult to accurately forecast the impact on the Group but it may be
unlikely that the Group could continue as a going concern. In such unfortunate circumstances the Directors
would most likely need to wind up the Group's operations in an orderly and timely fashion."
